Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmaceutical Sciences

Background:

• pH-responsive nanoplatforms are crucial for targeted drug delivery, particularly in acidic tumor microenvironments.
• Acetalated α-cyclodextrin offers a versatile base for engineering such nanomaterials with controllable properties.
• Paclitaxel (PTX) is a potent anticancer drug often limited by multidrug resistance and delivery challenges.

Purpose of the Study:

• To engineer novel pH-responsive nanoparticles using acetalated α-cyclodextrin for controlled drug delivery.
• To evaluate the pH-modulated hydrolysis, drug release kinetics, and biocompatibility of these nanocarriers.
• To assess the efficacy of paclitaxel-loaded pH-sensitive nanosystems against various cancer cells, including multidrug-resistant ones, and compare their performance in vivo.

Main Methods:

• Synthesis of pH-responsive nanoparticles via acetalation of α-cyclodextrin, controlling hydrolysis rates by acetal type and time.
• Incorporation of paclitaxel (PTX) into the pH-sensitive nanosystems.
• In vitro cytotoxicity assays against various tumor cell lines, including PTX-resistant cells.
• In vivo antitumor studies comparing the efficacy of the formulated nanomedicines with pristine PTX and PLGA nanoformulations.
• Comparative analysis with other acid-labile materials.

Main Results:

• Acetalated α-cyclodextrin nanoparticles exhibit tunable pH-modulated hydrolysis and pH-triggered drug release.
• The nanocarriers demonstrated good in vitro and in vivo biocompatibility.
• Paclitaxel-loaded pH-sensitive nanosystems showed significantly enhanced cytotoxic activity against tumor cells.
• These nanomedicines effectively reversed multidrug resistance in PTX-resistant cancer cells.
• In vivo studies indicated superior antitumor efficacy compared to pristine PTX and pH-insensitive PLGA nanoparticles.
• Cyclodextrin-based nanovehicles offered advantages in drug loading, activity, and reduced adverse effects over other acid-labile materials.

Conclusions:

• pH-responsive nanoparticles engineered from acetalated α-cyclodextrin provide a promising platform for controlled drug delivery.
• These nanocarriers demonstrate significant potential for enhancing anticancer therapy by improving drug efficacy and overcoming resistance.
• The developed nanomedicines represent a new generation of nanocarriers with potential for clinical translation in cancer treatment.